#USA #New York #LLC #Faruqi & Faruqi #Capricor

Investigation into Capricor Therapeutics

Faruqi & Faruqi, LLP, a renowned national securities law firm, is currently delving into possible claims regarding Capricor Therapeutics, Inc. This investigation comes in light of various challenges the company has faced, particularly concerning their lead cell therapy candidate, deramiocel, which is aimed at treating Duchenne muscular dystrophy. Investors who purchased or acquired Capricor securities between October 9, 2024, and July 10, 2025, are encouraged to review their legal options, especially as they may be eligible to act as lead plaintiffs in a federal securities class action slated for filing against the company.

Background of the Situation

Capricor has been a subject of scrutiny after it announced receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). This letter specifically cited that the company's Biologics License Application (BLA) for deramiocel did not meet statutory requirements for substantial evidence of its effectiveness. Concerns were also raised about the need for further clinical data. After the notice, Capricor's stock plummeted from $11.40 per share to $7.64, causing significant losses for many investors.

Within the legal realms, Faruqi & Faruqi is emphasizing the importance of addressing these adverse developments. The firm’s commitment to protecting investor rights has propelled them to investigate Capricor’s actions and communications, which may have been misleading or false regarding the efficacy and progress of their therapeutic candidate. Numerous statements made by company leaders regarding the positive outcomes expected from their clinical trials have now come into question. To this end, shareholders are urged to articulate their experiences and losses suffered during the indicated time frame to help bolster the case against the corporation.

How Faruqi & Faruqi Can Help

James (Josh) Wilson, a partner at Faruqi & Faruqi, is spearheading communications with affected investors. His team is offering prospective plaintiffs a chance to discuss their circumstances and explore options, which may include joining the growing group of investors looking to claim their losses. The firm highlights that without taking action, some investors might miss the opportunity to recover their investment losses if they decide not to pursue the lead plaintiff role or even abstain from participating in the lawsuit entirely.

If you have information regarding Capricor or believe you may have been misled by their corporate communications, you are encouraged to reach out. Faruqi & Faruqi is also welcoming testimonies from whistleblowers, former employees, and any shareholders who feel aggrieved by the company’s actions.

Conclusion

In the tumultuous world of healthcare securities, it is imperative for investors to stay informed and proactive. The investigation by Faruqi & Faruqi against Capricor Therapeutics underscores the ongoing efforts to hold corporations accountable. With the September 15, 2025 deadline for filing as lead plaintiffs looming, now is the time for investors to act. For those interested in getting involved or seeking more information, you can contact Faruqi & Faruqi directly and ensure your voice is heard in this critical matter.

Faruqi & Faruqi, LLP has a proud history of securing hundreds of millions of dollars on behalf of investors since 1995, and they remain dedicated to helping you navigate these challenges.

• ---

Contact Information
For further inquiries, contact Josh Wilson at 877-247-4292 or visit their website at www.faruqilaw.com for more details.